Q BioMed Inc. (QBIO) EPS Estimated At $-0.29 as of July, 18

June 27, 2018 - By Darrin Badillo

Q BioMed Inc. (OTCMKTS:QBIO) Corporate Logo

Q BioMed Inc. (OTCMKTS:QBIO)’s earnings report is awaited on July, 18., as reported by Faxor. The earnings per share diference is $0.00 or 0.00 % from last years number. Previous year: $-0.29; Analysts forcast: $-0.29. Wall Street now sees 70.59 % negative EPS growth despite Q BioMed Inc. previous quarter’s EPS of $-0.17. The stock increased 0.29% or $0.01 during the last trading session, reaching $3.42.Currently Q BioMed Inc. is after 0.00% change in last June 27, 2017. QBIO has 16,791 shares volume. QBIO underperformed by 12.57% the S&P500.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.The firm is worth $47.79 million. The firm offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer.Currently it has negative earnings. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: